The surveillance inspection, conducted from March 10 to March 14, 2025, concluded without any observations. On Thursday (March 13), shares of Zydus Lifesciences Ltd ended at ₹883.05, down by ₹5.95, or ...

Inspection occurred from March 10, 2025 to March 14, 2025 and ended with no observations with full compliance.

Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive ...

Zydus Lifesciences rose 1.67% to Rs 897.25 after the firm said that the US Food and Drug Administration (USFDA) conducted a surveillance inspection at the company's Active Pharmaceutical Ingredient ...

Zydus Lifesciences has announced that the US Food and Drug Administration (USFDA) conducted a surveillance inspection at the company's Active Pharmaceutical Ingredient (API) Unit 1, located in ...

The upgradation of the injectibles facility at Moraiya was completed and also, they expanded their manufacturing facility at Ankleshwar.Zydus Healthcare Brasil Ltd, Brazil, a wholly owned ...